Bluerock Mountain (North Carolina)

Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance

Retrieved on: 
Friday, January 27, 2023
AML, Mouse, Molecular logic gate, Stem cell, Society, ASH, CD33, VSIG2, Bluerock Mountain (North Carolina), IND, AAV, Senti Aur Mental, Technology transfer, Myelodysplastic syndrome, Gene, Spark Therapeutics, CGMP, HCC, Society for Immunotherapy of Cancer, Immunotherapy, Research, SNTI, CAR, MDS, NK, Patient, Colorectal cancer, NOT, FDA, Acute myeloid leukemia, TGF, FLT3, EMCN, SITC, CEA, Hepatocellular carcinoma, Doctor of Philosophy, Therapy, Vaccine, Pharmaceutical industry, MD

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology platform, today announced a strategic plan to focus internal resources on SENTI-202, SENTI-401 and, with potential partners, to continue to pursue the development of Gene Circuits for other programs, including solid tumors. The Company does not intend to invest in the clinical development of SENTI-301A, for the treatment of hepatocellular carcinoma (HCC), on its own at this time; however, the Company believes there is significant market opportunity for SENTI-301A, especially in territories within Asia where HCC is more prevalent than in the United States. Accordingly, the Company is actively pursuing strategic geographic partnerships for clinical development of SENTI-301A. This business realignment will streamline internal efforts and is expected to extend the Company’s cash runway through at least the first quarter of 2024.

Key Points: 
  • Accordingly, the Company is actively pursuing strategic geographic partnerships for clinical development of SENTI-301A.
  • This business realignment will streamline internal efforts and is expected to extend the Company’s cash runway through at least the first quarter of 2024.
  • “We are laser focused on developing cell therapies engineered with Gene Circuits to enable selective killing of tumor cells while protecting healthy cells.
  • Beyond oncology, the Company is continuing its strategic research collaborations with Spark Therapeutics on next-generation AAV gene therapy, and BlueRock Therapeutics on iPSC-derived cell therapies.

Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting

Retrieved on: 
Wednesday, November 23, 2022
CEA, SAN, Bluerock Mountain (North Carolina), Risk, Acute myeloid leukemia, Therapy, Social media, GPC3, CST, Research, Society, GMP, Security (finance), ASH, Vii, HCC, Leukemia, Synthetic biology, Spark Therapeutics, SNTI, CRC, COVID-19, Gene, AML, Colorectal cancer, FLT3, Hepatocellular carcinoma, Intelligence, CD33, Probability, Leukemia Research, MDS, File, Cancer, FAQ, KOL, Vaccine, Risk management, Senty Church, MSCI, IND, MD

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit technology platform, will host an Investor Event on December 11 during the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA.

Key Points: 
  • The Investor event will take place in-person and virtually and a webcast of the event will be available on Sentis Events & Presentations page.
  • This meeting is not an official program of the ASH annual meeting.
  • Senti Bio anticipates that subsequent events and developments may cause Senti Bios assessments to change.
  • Availability of Other Information About Senti Biosciences, Inc.
    For more information, please visit the Senti Bio website at https://www.sentibio.com or follow Senti Bio on Twitter (@SentiBio) and LinkedIn (Senti Biosciences).

Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
File, Synthetic biology, Spark Therapeutics, Research, DNA, SAN, U.S. Securities and Exchange Commission, Society, Hepatocellular carcinoma, Vii, SEC filing, Industry, GLOBE, Probability, Science, Gene, CRC, HCC, Form S-1, Securities Exchange Act of 1934, FLT3, Poster, ASH, Bluerock Mountain (North Carolina), Acute myeloid leukemia, COVID-19, Therapy, Nasdaq, CD33, Review, Colorectal cancer, Securities Act of 1933, EMCN, Selective, FAQ, Intelligence, Social media, SNTI, Forward-looking statement, Lymphatic system, Risk, Form, Security (finance), AML, SEC, GMP, Program, Vaccine, Risk management, Senty Church, IND

Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches.

Key Points: 
  • Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches.
  • 333-267390), filed with the SEC on September 12, 2022, and other documents filed by Senti Bio from time to time with the SEC.
  • Senti Bio anticipates that subsequent events and developments may cause Senti Bios assessments to change.
  • Availability of Other Information About Senti Biosciences, Inc.
    For more information, please visit the Senti Bio website at https://www.sentibio.com or follow Senti Bio on Twitter (@SentiBio) and LinkedIn (Senti Biosciences).

Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
SAN, LinkedIn, U.S. Securities and Exchange Commission, Securities Act of 1933, Risk, SEC filing, SEC, Therapy, Acute myeloid leukemia, Gene, Review, AML, Spark Therapeutics, SITC, Science, GMP, Bluerock Mountain (North Carolina), Intelligence, Synthetic biology, Form S-1, Hepatocellular carcinoma, Research, Twitter, Security (finance), Program, Annual general meeting, HCC, CRC, Nasdaq, Immunotherapy, Colorectal cancer, Probability, Industry, FAQ, Society, Form, Securities Exchange Act of 1934, Social media, Vii, File, GLOBE, SNTI, Forward-looking statement, DNA, COVID-19, Society for Immunotherapy of Cancer, Vaccine, Risk management, IND, Senti Virus

Information about the poster sessions is as follows:

Key Points: 
  • Information about the poster sessions is as follows:
    Following the presentations, copies of the posters will be available on the Scientific Presentations & Publications section of the Senti Bio website.
  • 333-267390), filed with the SEC on September 12, 2022, and other documents filed by Senti Bio from time to time with the SEC.
  • Senti Bio anticipates that subsequent events and developments may cause Senti Bios assessments to change.
  • Availability of Other Information About Senti Biosciences, Inc.
    For more information, please visit the Senti Bio website at https://www.sentibio.com or follow Senti Bio on Twitter (@SentiBio) and LinkedIn (Senti Biosciences).

Senti Bio to Participate in Chardan’s 6th Annual Genetic Medicines Conference

Retrieved on: 
Tuesday, September 20, 2022
Investor, CFO, FAQ, Twitter, Fireside chats, Spark Therapeutics, Securities Act of 1933, Colorectal cancer, LinkedIn, CRC, Review, Regulation, Social media, Synthetic biology, Therapy, Program, File, HCC, Intelligence, U.S. Securities and Exchange Commission, CEO, Event, Acute myeloid leukemia, Nasdaq, Bluerock Mountain (North Carolina), SNTI, SAN, Fireside, AML, DNA, GLOBE, Security (finance), Conference, Gene, Hepatocellular carcinoma, CMDO, Pharmaceutical industry, Vaccine

Tim Lu will also participate in a panel on Gene Regulation on Tuesday, October 4, 2022, at 9:30 AM ET.

Key Points: 
  • Tim Lu will also participate in a panel on Gene Regulation on Tuesday, October 4, 2022, at 9:30 AM ET.
  • A live webcast of the Fireside Chat can be accessed under the Events & Presentations section of the Senti Bio website under the Investors tab and will be available for 120 days following the presentation.
  • Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches.
  • Availability of Other Information About Senti Biosciences, Inc.
    For more information, please visit the Senti Bio website at https://www.sentibio.com or follow Senti Bio on Twitter (@SentiBio) and LinkedIn (Senti Biosciences).

NACD North Texas Announces New Chapter Officers and Board Members for 2022–2023

Retrieved on: 
Thursday, May 26, 2022
Consulting, Other Professional Services, Professional Services, Human Resources, Frost Brown Todd, Fraud, United Way, Southern Methodist University, Center, D Magazine, Eagle Materials, BGSF, Deloitte, Dallas–Fort Worth metroplex, The City: London and the Global Power of Finance, Business, NYSE, Health, Foley & Lardner, Cox School of Business, HR, Foley, Dallas Regional Chamber, JPMorgan Chase, Woman, NACD, Corporation, IBP, Atlantic Ocean, Education, EXP, Leadership, EfTEN Real Estate Fund III, American City Business Journals, Join, Corporate governance, Global, Akola, Technology, Cattle, North Texas Tollway Authority, Chairperson, CEO, Management, Indrajit, Bluerock Mountain (North Carolina), Truist Financial, D500

The NACD North Texas Chapter , the advocate for the profession of directorship, today announced the election of new officers and board members for 20222023, effective July 1, 2022.

Key Points: 
  • The NACD North Texas Chapter , the advocate for the profession of directorship, today announced the election of new officers and board members for 20222023, effective July 1, 2022.
  • Margot Carter has been selected as board chair of the NACD North Texas Chapter.
  • He is chairman of the board of directors of the North Texas Tollway Authority and board member of Mobility Credit Union.
  • NACD North Texas provides a forum for NACD members to exchange knowledge and discuss leading boardroom practices in the Dallas and Fort Worth area.

SHAREHOLDER ALERT: WeissLaw LLP Reminds GDNSF, ATVI, ZNGA, and BRG Shareholders About Its Ongoing Investigations

Retrieved on: 
Wednesday, February 9, 2022
NASDAQ, OTCQX, Microsoft, Multimedia, BRG, Verano, Activision Blizzard, NYSE, ZNGA, ATVI, Zynga, Bluerock Mountain (North Carolina), Acquisition, Online gambling, Property management

WeissLaw LLPis investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Goodness Growth Holdings, Inc. (OTCQX: GDNSF), in connection with the proposed acquisition of the company by Verano Holdings Corp. ("Verano").Under the terms of the acquisition agreement, each holder of GDNSF subordinate voting shares will receive 0.22652 of a Verano Class A subordinate voting share (a "Verano Share") for each voting share held and each holder of GDNSF multiple voting shares and GDNSF super voting shares will receive 22.652 Verano Shares for each respective voting share held.If you own GDNSF shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/gdnsf

Key Points: 
  • WeissLaw LLPis investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Goodness Growth Holdings, Inc. (OTCQX: GDNSF), in connection with the proposed acquisition of the company by Verano Holdings Corp. ("Verano").Under the terms of the acquisition agreement, each holder of GDNSF subordinate voting shares will receive 0.22652 of a Verano Class A subordinate voting share (a "Verano Share") for each voting share held and each holder of GDNSF multiple voting shares and GDNSF super voting shares will receive 22.652 Verano Shares for each respective voting share held.If you own GDNSF shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/gdnsf
    WeissLaw LLPis investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Activision Blizzard, Inc. (NASDAQ: ATVI), in connection with the proposed acquisition of ATVI by Microsoft Corporation.Under the terms of the acquisition agreement, ATVI shareholders will receive $95.00 in cash for each share of ATVI common stock that they hold.
  • If you own ATVI shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/atvi
    WeissLaw LLPis investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Zynga, Inc. (NASDAQ: ZNGA), in connection with the proposed acquisition of ZNGA by Take-Two Interactive Software, Inc. ("Take-Two").Under the terms of the merger agreement, ZNGA stockholders will receive $3.50 in cash and $6.36in shares of Take-Two common stock for each share of ZNGA common stock that they hold.
  • If you own ZNGA shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/znga
    WeissLaw LLPis investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Bluerock Residential Growth REIT, Inc. (NYSE: BRG), in connection with the proposed acquisition of BRG by affiliates of Blackstone Real Estate.Under the terms of the agreement, BRG shareholders will receive $24.25 in cash and shares of the newly formed real estate investment trust named Bluerock Homes Trust, Inc., with a current implied Net Asset Value estimated at $5.60, for each share of BRG common stock that they hold.If you own BRG shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslaw.co/news-and-cases/brg
    View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-...

BlueRock Therapeutics Announces New Board Chair, New President and CEO

Retrieved on: 
Monday, July 26, 2021
Companies, Industry economics), Aspirin, Bayer, IG Farben, Leverkusen, Economy of Germany

CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of BayerAG, announcedtodaythat Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021.

Key Points: 
  • CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of BayerAG, announcedtodaythat Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021.
  • Current Chief Scientific Officer Seth Ettenberg, Ph.D., will assume the role of President and CEO.
  • BlueRock will continue in its mission to create authentic cellular medicines to reverse devastating diseases and improve the human condition.
  • BlueRock also recently initiated a first-of-its-kind trial of pluripotent stem-cell derived dopaminergic neurons in patients with advanced Parkinson's disease.